Amarin Corp Plc (AMRN)

[Biobillionair]

New study BP should read:
Eur Heart J. 2013 February 21; 34(8): 615–624.

Statins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesion
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3578265/

Amarin's newly published results:
In Amarin's MARINE and ANCHOR trials, the 4 gram dose of Vascepa achieved reductions in Apo C-III levels of 25.1% (p < 0.0001) and 19.2% (p < 0.0001) compared to placebo, respectively.
http://finance.yahoo.com/news/amarin-announces-clinical-data-showing-100000785.http

The Apo C 3 topic is heating up:
-------------------------
Research Shows Antisense Inhibition of ApoC-III and Triglycerides in Multiple Species Including Humans
CARLSBAD, Calif., April 1, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the publication of new data in the journal Circulation Research [doi:10.1161/CIRCRESAHA.111.300367] demonstrating that antisense targeting of apolipoprotein C-III (apoC-III)
http://ir.isispharm.com/phoenix.zhtml?c=222170&p=irol-newsArticle&id=1801803

APOC3 apolipoprotein C-III [ Homo sapiens (human) ]
Gene ID: 345, updated on 7-Apr-2013
http://www.ncbi.nlm.nih.gov/gene/345
------------------------
APOC3 is a good indication in which direction we see REDUCE-IT heading.